Other languages Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq Other stock markets 04:30:01 2024-05-06 pm EDT			5-day change	1st Jan Change
2.12 ^USD	+1.92%		+6.53%	-29.10%

Mar. 25	Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol	DJ
Mar. 25	Sector Update: Health Care Stocks Steady Premarket Monday	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Steady Premarket Monday	Mar. 25
Top Premarket Gainers	Mar. 25
U.S. FDA Approves Broad New Labels for Esperion?s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use	Mar. 22
Esperion Therapeutics Shares Rise After US FDA Expands Labels for Nexletol, Nexlizet	Mar. 22
Esperion, Daiichi Get EU Committee Recommendation For Nilemdo, Nustendi Label Update	Mar. 22
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Announces CHMP Adopts Positive Opinions for the Label Update of Both Bempedoic Acid and the Bempedoic Acid / Ezetimibe Fixed Dose Combination	Mar. 22
Esperion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Esperion Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	Jan. 19
US Futures Trend Higher as Investors Await Consumer Sentiment, Home Sales Data	Jan. 19
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Friday Amid Tech Stocks Gains	Jan. 19
Top Premarket Decliners	Jan. 19
Esperion Therapeutics Prices $85.1 Million Share Offering	Jan. 19
Esperion Therapeutics Launches Share Offering	Jan. 18
Top Midday Decliners	Jan. 03
Esperion Therapeutics, Daiichi Sankyo Europe Settle Commercial Dispute With $125 Million Amendment in Collaboration	Jan. 03
Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including Resolution of Pending Litigation	Jan. 03
U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet	Dec. 13
Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023	Nov. 11
Esperion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Other languages

Filters